Progress and achievements of incentive policy reform for innovative drugs in China
Innovation is the main theme of the pharmaceutical industry,and the progress of innovative drug development is in turn an important symbol of the innovative ability of the pharmaceutical industry.This paper systematically composes the important incentive policies for the development of innovative drugs since 2015 in China,and finds that the domestic innovation ecology has changed dramatically.The definition of innovative drugs has shifted from"new in China"to new"in the world".The vitality of innovative subjects has been released,with significant improvements in innovative drug R&D,clinical trial,review and approval,communication mechanism,patent protection,medical insurance access,terminal landing,and capital assistance compared to that before 2015.Under this favorable background,the number of approved innovative drugs and the proportion of domestic products have increased,the market size of different sales terminal has grown steadily,and the number of innovative products included in the national medical insurance drug list has increased year by year.In the future,more attention should be paid to multi-chain synergy,policy implementation details,possible side effects brought by the policy implementation,and the measures we could take to avoid these side effects.
innovative drugincentive policyprogress of reformachievements of reform
NETL
NSTL
万方数据
